INVESTORS
01 — INVESTMENT OVERVIEW
Ounce Sachs is a proprietary healthcare and consumer IP platform commercialising defensible formulations across a portfolio of premium brands, supported by independently valued intellectual property and a defined public-markets growth strategy.
02 — MARKET & SECURITY INFORMATION
INDICATIVE EQUITY VALUE PER SHARE
$0.0753
INDICATIVE EQUITY VALUATION
$37,663,543
SHARES OUTSTANDING
500,000,000
CAPITAL RAISE
Institutional Participation
INVESTMENT STATUS
Private Capital Raise
SECURITY TYPE
Common Stock
Long-term STRATEGIC OBJECTIVE
Nasdaq Listing
Indicative equity value per share is calculated by reference to the current indicative equity valuation and 500,000,000 shares outstanding. The Company is currently pursuing a private capital raise. Any future Nasdaq listing remains a long-term strategic objective and is subject to applicable corporate, regulatory and market requirements.
Ounce Sachs Inc. is undertaking a private placement of its common stock to eligible investors pursuant to applicable exemptions from registration under the U.S. Securities Act of 1933.
UNITED STATES
Regulation D — Rule 506(c)
Available exclusively to accredited investors. Investor eligibility and accredited investor status will be subject to verification prior to acceptance of any subscription.
INTERNATIONAL
Regulation S
Available to qualifying non-U.S. persons participating in offshore transactions, subject to applicable securities laws and jurisdictional restrictions.
03 — INDEPENDENT VALUATION
VALUATION DATE — 2 August 2026
INDEPENDENT VALUATION FIRM — ABM Sanaullah & Co.
VALUATION METHODOLOGY — Relief-from-Royalty
VIEW INDEPENDENT VALUATION
04 — CORPORATE & CAPITAL PARTNERS
Professional appointments
CAPITAL MARKETS PARTNER
TBC
INDEPENDENT AUDITOR
Mercurius Advisory Services Pvt. Ltd.
INDEPENDENT VALUATION ADVISER
ABM Sanaullah & Co.
SECURITIES COUNSEL
TBC
REGISTERED AGENT
Advantage Delaware LLC
Diversified Group & Brand Portfolio
Portfolio spanning healthcare, personal care and consumer brands.
Proprietary Intellectual Property
Commercial platform supported by internally developed and independently valued intellectual property.
Commercialisation Strategy
Focused on disciplined market expansion, product development and scalable brand growth.
Current Private Capital Raise
Capital being raised to support the next phase of commercial and institutional development.
Strategic Use of Capital
Proceeds directed toward commercialisation, working capital, regulatory expansion, corporate development and capital-markets execution.
Long-Term Capital Markets Objective
Building the corporate, financial and governance infrastructure required to support the Company’s long-term public-market strategy.
Use of Proceeds
Capital raised is intended to support the disciplined development of the Group’s commercial and institutional platform.
Product Commercialisation
Working Capital
Regulatory & Market Expansion
Corporate Development
Capital Markets Execution
05 — INVESTOR DOCUMENT LIBRARY
Investor Presentation
Independent Valuation
VIEW PDF →
Corporate Overview
Financial Information
Capital Structure
Corporate Documents
Securities offered pursuant to Regulation D may constitute restricted securities and are subject to applicable transfer restrictions. Investment opportunities are available only to eligible investors and any investment will be made solely pursuant to definitive offering and subscription documentation.
06 — PRIVATE CAPITAL RAISE | REGULATION D 506(c) and Regulation s
Capital Markets & Investor Access
Institutional investor communications and access to offering materials are administered through the Company’s appointed capital markets partner.
Investor enquiries, eligibility assessment, access to offering materials and subscription administration
are managed through the Company’s appointed capital markets partner.
INSTITUTIONAL ENQUIRIES